Market Watch
16 Nov 2026, 13:01 UTC · 12h ago
The FDA declined to approve one of biotech's most closely watched cancer drugs
Impact · against what's priced in
Summit Therapeutics faces a significant valuation hit as the FDA's refusal to approve ivonescimab removes the immediate catalyst the market was relying on. The requirement for additional survival data directly undermines the current price support for the drug's regulatory path and pushes revenue generation further into the future.
- SMMT−0.70
Challenges what's priced in
- The price assumes
The FDA acceptance of the ivonescimab Biologics License Application with a November 2026 PDUFA date
The market treated the November 2026 PDUFA date as a known procedural step toward approval; the FDA's decision to decline approval and demand further evidence on survival rates fundamentally breaks that assumption.
What SMMT's price assumes · Sep 24

Top 1 mover · tap to explore




